Tesaglitazar, a dual PPAR-α/γ agonist, hamster carcinogenicity, investigative animal and clinical studies (Q42723223)

5 November 2017

Tesaglitazar, a dual PPAR-α/γ agonist, hamster carcinogenicity, investigative animal and clinical studies (English)

1 reference

5 November 2017

Per Lindblom

1

1 reference

5 November 2017

Anna-Lena Berg

2

1 reference

5 November 2017

Hui Zhang

3

1 reference

5 November 2017

Rolf Westerberg

4

1 reference

5 November 2017

Jonathan Tugwood

5

1 reference

5 November 2017

Hanna Lundgren

6

1 reference

5 November 2017

Maritha Marcusson-Ståhl

7

1 reference

5 November 2017

Niclas Sjögren

8

1 reference

5 November 2017

Bo Blomgren

9

1 reference

5 November 2017

Peter Öhman

10

1 reference

5 November 2017

Inger Skånberg

11

1 reference

5 November 2017

John Evans

12

1 reference

5 November 2017

Heike Hellmold

13

1 reference

5 November 2017

language of work or name

English

0 references

publication date

30 November 2011

1 reference

5 November 2017

Toxicologic Pathology

1 reference

5 November 2017

40

1 reference

5 November 2017

1

1 reference

5 November 2017

18-32

1 reference

Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism

5 November 2017

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Review of the hepatic response to hypolipidaemic drugs in rodents and assessment of its toxicological significance to man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Effects of PPARgamma and combined agonists on the urinary tract of rats and other species

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Hemangiosarcoma in rodents: mode-of-action evaluation and human relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

[Spontaneous tumors in Syrian golden hamsters (author's transl)].

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Histopathology of hemangiosarcomas in mice and hamsters and liposarcomas/fibrosarcomas in rats associated with PPAR agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Peroxisome proliferator-activated receptor gamma mediated inhibition of plasminogen activator inhibitor type 1 production and proliferation of human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

PPARbeta/delta selectively induces differentiation and inhibits cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Transgenic rabbits with increased VEGF expression develop hemangiomas in the liver: a new model for Kasabach-Merritt syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Effects of microsomal enzyme inducers on thyroid follicular cell proliferation and thyroid hormone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

PPARalpha agonist-induced rodent tumors: modes of action and human relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Mechanisms of hepatocarcinogenicity of peroxisome-proliferating drugs and chemicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

The many faces of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Short and long-term effects of hVEGF-A(165) in Cre-activated transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

The significance of hepatic microsomal enzyme induction and altered thyroid function in rats: implications for thyroid gland neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

A framework for human relevance analysis of information on carcinogenic modes of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Progressive proliferative and dysplastic typhlocolitis in aging syrian hamsters naturally infected with Helicobacter spp.: a spontaneous model of inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Spontaneous Tumors and Common Diseases in Two Colonies of Syrian Hamsters. II. Respiratory Tract and Digestive System2

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623311429972

21 January 2018

Identifiers

DOI

10.1177/0192623311429972

1 reference

5 November 2017

1 reference